

Medibio collaborates with University of Ottawa on research

Sydney, Australia – 12 October 2015: Medibio Limited (MEB or the Company) is pleased to announce that it has entered into a research agreement with The Royal's Institute of Mental Health Research (IMHR), affiliated with the University of Ottawa, to undertake a study titled *"Detailed Analysis of Sleep Physiology in Mental Disorders"*. The aim of the study is to assess the validity and specificity of MEB's CHR technology to discriminate between individuals with mental disorders, individuals with sleep disorders, and healthy controls. The study will be the first to expand beyond depression, evaluating subjects with anxiety, bipolar and psychotic disorders in addition to depression.

About The Royal's Institute of Mental Health Research, proudly affiliated with the University of Ottawa

The Royal is one of Canada's foremost mental health care and academic health science centres. Its mandate is simple: to help more people living with mental illness into recovery faster. The Royal combines the delivery of specialized mental health care, advocacy, research and education to transform the lives of people with complex and treatment resistant mental illness. The Royal's Institute of Mental Health Research (IMHR) strives to continuously improve mental health and well-being through leadership, collaborative discoveries and innovation in research, patient care and education. The IMHR's "neuron to neighborhood" approach examines mental illness on a continuum that spans basic biology to the level of the community itself.

The IMHR is proudly affiliated with the University of Ottawa. The University of Ottawa Department of Psychiatry comprises 231 faculty members and has continually shown its commitment to the development of mental health care and mental health research on a national and international scale.

Principal Researcher

The Principal Researcher for the study will be Dr. Rebecca Robillard. Dr Robillard is a researcher at the IMHR and the Centre for Advanced Research on Sleep Medicine in Canada. Her current work focuses on characterising the circadian profile associated with various psychiatric conditions, including schizophrenia, major depression and bipolar disorder. Her aim is to better understand the relation between sleep/circadian disturbances and psychiatric illnesses, notably to inform new treatment pathways.

Objectives of the Study

The study is part of a larger program investigating sleep biomarkers of mental disorders across multiple age groups. The main aim of this specific sub-study is to:

1. Compare patients with anxiety, depression, bipolar and psychotic disorders in terms of variations in heart rate during transitions across wake and sleep states
2. Evaluate the relative associations between heart rate variations, age, psychiatric symptoms severity, and psychotropic medications
3. Assess the validity and specificity of MEB's diagnostic algorithms using heart rate variations during sleep to discriminate between individuals with mental disorders (with and without comorbid sleep disorders), individuals with sleep disorders (without psychiatric illnesses) and healthy controls.

Overall, participants will be divided into the following primary diagnosis subgroups:

- A) Mental disorders (with and without diagnosis of sleep disorders): anxiety disorders (e.g. generalised anxiety disorder, panic disorder, post-traumatic stress disorder), depressive syndromes (e.g. major depressive disorder, dysthymia), bipolar disorder and psychotic disorders (e.g. schizophrenia, schizoaffective disorder, brief psychotic disorder)
- B) Sleep disorders (without any diagnosis of a mental disorder): insomnia, sleep-disordered breathing, restless leg syndrome or periodic limb movement disorder and parasomnias (e.g. REM sleep behaviour disorder, somnambulism)
- C) Healthy controls

The study is a retrospective study with data to be extracted from the Royal Ottawa Mental Health Centre (ROMHC) Sleep Clinic existing database. This will allow results to be generated quickly for peer review and publishing. An expected timetable for completion will be provided as it becomes available.

End

Further Information:		Website: www.medibio.com.au
Medibio Shareholder Enquiries to: Kris Knauer CEO and Director Medibio Limited kris.knauer@medibio.com.au T: +61 (0)411 885979	Medibio Media Enquiries to: Peter Taylor NWR Communications Peter@nwrcommunications.com.au T: +61 (0)412 036 231	

ABOUT MEDIBIO LIMITED

Medibio (ASX: MEB), is a medical technology company developing a new objective test to assist in the diagnosis of depression, other mental health disorders, and chronic stress. This test utilizes circadian heart rate variability. The technology is based on research conducted over 15 years and studies are currently being undertaken by Johns Hopkins University School of Medicine and the University of New South Wales to validate its clinical utility. The technology consists of a heart monitor that sends ECG recordings wirelessly to the cloud where proprietary algorithms analyse and deliver a quantifiable measure which can be used by a clinician to assist in diagnosis. The technology has the potential to be the first FDA approved objective, evidence based approach to the diagnosis of depression and other mental health disorders. Medibio is not just a traditional medical device company with revenue dependent upon regulatory approval. It has the only new and credible method for the diagnosis of stress and mental wellbeing which can be easily translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Sydney, NSW, Medibio is listed on the Australian Stock Exchange.